Compare iShares Global Clean Energy ETF (ICLN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Novartis AG — how do they compare? iShares Global Clean Energy ETF trades at $17.28 (market cap $2.30B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 119.1× iShares Global Clean Energy ETF's market cap, and Novartis AG pays a 3.31% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Novartis AG for 82 Days on average.
| ICLN | NVS | |
|---|---|---|
Market Cap | $2.30B | $274.00B |
Volume | 3,661,617 | 1,852,137 |
52-Week High | $23.75 | $168.62 |
52-Week Low | $15.78 | $121.80 |
Typical Hold Time | 87 Days | 82 Days |
Sector | — | Health |
Enterprise Value | — | $315.32B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.31, down 1.31% with a bearish technical signal from moving averages. The ETF faces volatility with clean energy exposure showing deeper drawdowns compared to traditional energy peers. Recent news highlights competitive pressure from fossil fuel ETFs delivering stronger returns and lower fees, though geopolitical tensions are accelerating global renewable energy adoption.
The outlook remains challenged by high expense ratios and sector volatility, but long-term growth potential exists from global energy transition trends. Key risks include competitive pressure from traditional energy and execution challenges in renewable adoption timelines.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
